A half-dozen Bay Area startups announced early stage funding during the last 24 hours. They include a business specializing in anti-hacking technology for mobile devices, a gastrointestinal-focused pharmaceutical (Read more...)
After acquiring ViroPharma last year in a $4.2 billion deal focused on Cinryze, the Irish pharmaceutical giant Shire says it is following through on a four-year-old (Read more...)
In biotech, there are quick flips, and there is what Flexus Biosciences managed to accomplish today. Just over a year after emerging from stealth, the San Carlos, CA-based (Read more...)
San Diego-based Cebix, which raised about $50 million to advance a C-peptide replacement therapy for treating diabetes-related microvascular problems, has quietly folded its tent.
Jacob Fuchs, an (Read more...)
Vertex Pharmaceuticals is a pillar of Boston biotech. A pioneer of treatments for hepatitis C and more recently, cystic fibrosis, the Boston-based company today is worth more than (Read more...)
Women’s health-focused biopharmaceutical researcher Evestra is taking a $5 million loan from existing partner Gedeon Richter so that it can further develop a product line that includes a (Read more...)
TraceLink, a company that sells a cloud-based platform tracking pharmaceutical drugs, has raised a $20 million Series B funding round to develop its products and build a (Read more...)
Laguna Pharmaceuticals, founded in 2006 as a spinout of Cleveland, OH-based drug discovery and testing company ChanTest, has raised $30 million in a Series B round of (Read more...)
Unchained Labs can now say it has financial stability after raising $25 million in Series A funding from venture capital investors Novo Ventures, Canaan Partners, and TPG Biotech.
Houston’s Fannin Innovation Studio has spun out its latest company, a biotech called Acelerox that aims to use nanoparticle technology to treat a variety of autoimmune and other (Read more...)
Cidara Therapeutics grabbed $42 million in a Series B funding round Wednesday to continue developing its treatment for fungal infections, a therapy that it expects will hit the (Read more...)
Gilead Sciences (NASDAQ: GILD) is deep into a campaign to defend its hepatitis C drug franchise from price attacks, and its executives are fighting back with tough (Read more...)
Healthcare startups have for years built businesses on the principle of ridding the system of inefficiencies and extra costs for years. Two more gained venture backing today.
DigiSight (Read more...)
In 1998, Xconomist Roger Newton co-founded a company called Esperion Therapeutics and drove the development of atorvastatin (Lipitor), a blockbuster cholesterol-lowering statin drug that is reportedly the most (Read more...)
Running a large, expensive cardiovascular study is no easy feat for a small biotech. That’s why the $24.3 million Armetheon raised in a Series B round last (Read more...)